Catherine I Starner
Overview
Explore the profile of Catherine I Starner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
187
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marshall L, Espinosa R, Starner C, Gleason P
J Manag Care Spec Pharm
. 2023 Jun;
29(6):599-606.
PMID: 37276039
Cystic fibrosis (CF) is a chronic, progressive genetic disease caused by mutations in the CF transmembrane conductance regulator () gene resulting in a dysfunctional CFTR protein. Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) is a...
2.
Starner C, Bowen K, Gleason P
J Manag Care Spec Pharm
. 2022 Oct;
28(11):1200-1206.
PMID: 36282927
As new rare-disease drug therapy, gene therapies, and high-priced cancer drugs receive US Food and Drug Administration approval, there is an increasing potential for drug super spender individuals with more...
3.
Starner C, Gleason P
J Manag Care Spec Pharm
. 2019 Nov;
25(12):1306-1308.
PMID: 31778615
No funding supported the writing of this commentary. The authors are employed by Prime Therapeutics, a pharmacy benefits management company.
4.
Starner C, Qiu Y, Karaca-Mandic P, Gleason P
J Manag Care Spec Pharm
. 2016 Nov;
22(12):1403-1410.
PMID: 27882841
Background: Patients often misuse a combination of prescription drugs including opioids; however, the relationship between a controlled substance (CS) score and health outcomes is unknown. Objective: To examine the association...
5.
Sofosbuvir initial therapy abandonment and manufacturer coupons in a commercially insured population
Karmarkar T, Starner C, Qiu Y, Tiberg K, Gleason P
Am J Manag Care
. 2016 Jun;
22(6 Spec No.):SP191-7.
PMID: 27266948
Objectives: To describe rates of sofosbuvir initial medication adherence as a function of the insurer-required member cost (ie, out-of-pocket cost) and to determine how manufacturer coupons affect insurer-required member cost....
6.
Starner C, Alexander G, Bowen K, Qiu Y, Wickersham P, Gleason P
Health Aff (Millwood)
. 2014 Oct;
33(10):1761-9.
PMID: 25288420
Expenditures for specialty drugs account for more than 25 percent of total US drug spending and have been increasing at more than 13 percent annually. We examined insurers' role in...
7.
Gleason P, Alexander G, Starner C, Ritter S, Van Houten H, Gunderson B, et al.
J Manag Care Pharm
. 2013 Aug;
19(7):542-8.
PMID: 23964615
Background: Drugs are most typically defined as specialty because they are expensive; however, other criteria used to define a drug as specialty include biologic drugs, the need to inject or...
8.
Gleason P, Phillips J, Fenrick B, Delgado-Riley A, Starner C
J Manag Care Pharm
. 2013 Feb;
19(1):18-25.
PMID: 23383704
Background: Dalfampridine (Ampyra) is indicated to improve walking in patients with multiple sclerosis (MS) and was found to be effective in 35%-43% of individuals with MS in clinical trials. Dalfampridine...
9.
Generic drug discount programs: are prescriptions being submitted for pharmacy benefit adjudication?
Tungol A, Starner C, Gunderson B, Schafer J, Qiu Y, Gleason P
J Manag Care Pharm
. 2012 Dec;
18(9):690-700.
PMID: 23206212
Unlabelled: Background: In 2006, pharmacies began offering select generic prescription drugs at discount prices (e.g., $4 for a 30-day supply) through nonmembership and membership programs. As part of the contract...
10.
Starner C, Fenrick B, Coleman J, Wickersham P, Gleason P
J Manag Care Pharm
. 2012 Apr;
18(3):225-33.
PMID: 22468731
Background: Prior authorizations (PA) are intended to promote safe and cost-effective medication use. Unwanted outcomes may occur, however, such as a patient forgoing drug therapy after a PA. The label...